Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
Elkhart General Hospital, Elkhart, Indiana, United States
Memorial Hospital of South Bend, South Bend, Indiana, United States
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Kantonsspital - St. Gallen, St. Gallen, Switzerland
Centro di Riferimento Oncologico - Aviano, Aviano, Italy
Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Finley Hospital, Dubuque, Iowa, United States
Santa Clarita Valley Cancer Center - UCLA, Valencia, California, United States
Charles A. Sammons Cancer Center, Dallas, Texas, United States
Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland, Ohio, United States
Elkhart General Hospital, Elkhart, Indiana, United States
Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States
Kingsbury Center for Cancer Care at Cheshire Medical Center, Keene, New Hampshire, United States
National Cancer Institute (NCI), Bethesda, Maryland, United States
Pfizer Investigational Site, Wythenshawe, Manchester, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.